BioInvent has a long history and a strong position in the generation and development of antibody drugs. The foundation of the company is expertise in immunology, cancer biology and antibody biology. Today, BioInvent is a company with multiple clinical programs ongoing.
The unique development tool F.I.R.S.T™, where patient material is the foundation throughout the development process, simultaneously identifies the clinically most relevant targets in a disease model and matching antibodies. The proprietary antibody library n-CoDeR® contains antibodies that bind specifically and strongly to their targets.
BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. The company has one of the most exciting and unique cancer immunotherapy pipelines of any European biotech company. View our Clinical Pipeline.
A solid scientific understanding, a clear clinical development strategy, and a robust capacity to execute plans have put the company on a very promising track to develop treatments capable of transforming the life of cancer patients.
BioInvent’s screening platform F.I.R.S.T™, where patient material is the foundation throughout the discovery and development process, identifies both clinically relevant targets and matching antibodies. The proprietary antibody library n-CoDeR® contains antibodies that bind specifically and strongly to their targets.
BioInvent Manufacturing, the contract manufacturing business unit of BioInvent International AB, has a proven track record for clients and partners since 1988. Using single use technology for more than 25 years, BioInvent Manufacturing has produced drug substance for clinical trials in Europe, the USA, Japan and Australia.
BioInvent is broadening and developing an exciting pipeline of innovative immuno-oncology therapies, based on its unique F.I.R.S.T™ technology platform and n-CoDeR® antibody library.
In this section you find all press releases, planned and past events as well as an image bank.
We are happy to answer any questions, don't hesitate to reach out to us!
Årsredovisning 2012
